Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Tag: AACR D3 2026
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO,...
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...